Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Anavex Life Sciences Corp announces ANAVEX 3-71 highly effective and disease-modifying against all major Alzheimer's hallmarks in preclinical disease model


Monday, 14 Jul 2014 07:27am EDT 

Anavex Life Sciences Corp:Says has unveiled promising preclinical data for ANAVEX 3-71 (formerly AF710B) in a presentation at the 2014 Alzheimer's Association International Conference (AAIC).Says data shows ANAVEX 3-71 to be disease modifying and highly effective in very small doses at countering the effects of major Alzheimer's hallmarks in a transgenic mouse model 3xTg-AD.Says those hallmarks include cognitive deficits, amyloid and tau pathologies, as well as neuroinflammation and mitochondrial dysfunctions.Reducing these major hallmarks has the potential to slow, stop or reverse Alzheimer's disease.Says ANAVEX 3-71 indicates extensive therapeutic advantages in Alzheimer's and other protein-aggregation-related diseases given its ability to enhance neuroprotection and cognition via sigma-1 receptor activation and M1 muscarinic allosteric modulation. 

Company Quote

0.199
 +0.10%
11:42am EST